Flex Pharma (NASDAQ: FLKS) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare Flex Pharma to related businesses based on the strength of its dividends, risk, analyst recommendations, valuation, earnings, profitability and institutional ownership.
This is a summary of recent recommendations for Flex Pharma and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Flex Pharma Competitors||882||3266||11754||235||2.70|
This table compares Flex Pharma and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Flex Pharma Competitors||-5,310.77%||-218.27%||-39.48%|
Insider and Institutional Ownership
27.3% of Flex Pharma shares are owned by institutional investors. Comparatively, 49.9% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 45.4% of Flex Pharma shares are owned by insiders. Comparatively, 16.9% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Flex Pharma and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Flex Pharma||$1.01 million||-$39.49 million||-1.62|
|Flex Pharma Competitors||$284.49 million||$34.10 million||79.53|
Flex Pharma’s competitors have higher revenue and earnings than Flex Pharma. Flex Pharma is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Flex Pharma Company Profile
Flex Pharma, Inc. is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. The Company operates through developing and commercializing products for nocturnal leg cramps, muscle cramps, spasms and spasticity associated with severe neuromuscular conditions, and exercise-associated muscle cramps segment. The Company’s lead drug product candidate is FLX-787, which is in the Phase II clinical trial stage. It is developing a consumer brand and products specifically formulated to treat athletes suffering from EAMCs.
Receive News & Ratings for Flex Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flex Pharma and related companies with MarketBeat.com's FREE daily email newsletter.